Current Report Filing (8-k)
October 04 2018 - 4:33PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 2, 2018
REGEN
BIOPHARMA, INC.
(Exact
name of small business issuer as specified in its charter)
Nevada
|
45-5192997
|
(State
or other jurisdiction of incorporation or organization)
|
(I.R.S.
Employer Identification No.)
|
Commission
File No. 333-191725
4700
Spring Street, St 304, La Mesa, California 91942
(Address
of Principal Executive Offices)
(619)
702 1404
(Issuer’s
telephone number)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
7.01. Regulation FD Disclosure.
On
October 2, 2018 Regen BioPharma, Inc., a Nevada corporation (the “Company”) received a letter from the staff at the
Division of Enforcement of the Securities and Exchange Commission indicating that the staff at the Division of Enforcement has
commenced an investigation into whether the Company timely filed its Form 8-K on March 31, 2017 and whether the Form 8-K was substantively
deficient. The Company is undertaking appropriate steps to investigate and evaluate the questions raised by the letter and otherwise
respond to the inquiry.
Item
8.01. Other Events
On
October 2, 2018 Regen BioPharma, Inc., a Nevada corporation (the “Company”) received a letter from the staff at the
Division of Enforcement of the Securities and Exchange Commission indicating that the staff at the Division of Enforcement has
commenced an investigation into whether the Company timely filed its Form 8-K on March 31, 2017 and whether the Form 8-K was substantively
deficient. The Company is undertaking appropriate steps to investigate and evaluate the questions raised by the letter and otherwise
respond to the inquiry.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
REGEN
BIOPHARMA, INC.
|
|
|
Dated: October 4,
2018
|
By:
/s/
David Koos
|
|
David Koos
|
|
Chief Executive Officer
|
Regen Biopharma (PK) (USOTC:RGBPP)
Historical Stock Chart
From Apr 2024 to May 2024
Regen Biopharma (PK) (USOTC:RGBPP)
Historical Stock Chart
From May 2023 to May 2024